Rational Combinations 360° Speakers
Oliver Manzke, MD
Executive Director, Global Clinical R&D
Oliver Manzke received his medical education and subsequent post graduate training in hemato-oncology at the University Clinic of Cologne, Germany. He holds a qualification as university lecturer (“habilitation”) for Experimental Internal Medicine and is a member of the Medical Faculty in Cologne.
During his academic career, he focused on the immunology and immunotherapy of cancers and has led several early-phase “proof of concept” immunotherapy studies in hemato-oncologic diseases. These focused on active immunotherapy approaches with T-cell engaging bispecific antibodies and with tumor-specific vaccines with antigen-presenting cells.
After academia, Oliver in 2001 moved to a biotech company evaluating tumor-specific immunotherapeutic approaches and in 2004 joined Bayer Germany where he was Global Medical Expert for Antiinfectives and Oncology. From 2006 to 2011, Oliver joined F. Hoffmann-La Roche in Basel where he held positions of increasing responsibility including the Global Clinical Lead for MabThera®/Rituxan®.
In 2011, Oliver joined the Global Clinical Development team for Hemato-Oncology at Celgene as the European Lead for lymphoma and CLL. He is currently the Global Program Lead for durvalumab in the Immuno-Oncology Team. In this function, he coordinates the Celgene Durvalumab clinical development program across the hemato-oncology therapeutic areas and with external collaboration partners.